Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Japanese pluripotent stem cell trial receives ethical approval

18 February 2013

By Reuben Harwood

Appeared in BioNews 693

What would be the first clinical trial to use induced pluripotent stem (iPS) cells has been granted ethical approval in Japan.

Researchers hope to use iPS cells to treat a common eye condition called age-related macular degeneration (AMD). The study aims to demonstrate the safety of a procedure using the cells. If the trial is approved by the Japanese Health Ministry, it could be underway before March 2014, reports the Nature News blog.

The damage to the eyes that occurs in AMD causes reduced vision, which can lead to blindness if left untreated. Currently there is no cure, although drugs exist that can halt the progression of the disease in a minority of cases.

Dr Masayo Takahashi of the Centre for Developmental Biology in Kobe, Japan, has now received conditional approval for the trial from the review board of the Institute for Biomedical Research and Innovation (IBRI). According to Nature News, the IBRI will also sponsor the trial.

Should the final round of preclinical experiments be successful, six patients over the age of 50 who are not responding to existing drugs would be enrolled.

In the procedure, scientists propose to first generate iPS cells from each patient's cells. They would then use these iPS cells to form epithelial cells, the type of cell that is damaged in AMD. The damaged epithelial layer would then be removed from the patients' eyes and replaced with a sheet made from these new cells.

As the first trial would be to test the safety of the procedure, it is not expected to reverse the eye damage in AMD. Although the researchers would hope for some signs that the treatment is working.

SOURCES & REFERENCES
Nature News | 14 February 2013
 
National Review Online | 14 February 2013
 
Global Post | 14 February 2013
 
Japan Daily Press (press release) | 14 February 2013
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 March 2017 - by Paul Waldron 
In two different attempts to treat degenerative eye diseases with stem cells, three patients have been blinded, while disease progression has been stopped in a separate patient...
28 June 2013 - by Rhys Baker 
A Japanese Health Ministry panel has approved the first use of induced pluripotent stem cells (iPS cells) in human trials...
03 June 2013 - by Nishat Hyder 
The Italian Senate has approved an 18-month, €3 million clinical trial of a controversial stem cell-based therapy. The vote, on 22 May 2013, will also allow a hospital to continue to treat twelve patients already undergoing the contested treatment...
03 June 2013 - by Dr Amina Aitsi-Selmi 
The first human trials of synthetic blood look set to go ahead in the UK...
04 March 2013 - by Dr Greg Ball 
Mouse embryonic stem cells are being transported to the International Space Station (ISS) to investigate the impact of long-term space flight on human health....

08 October 2012 - by Antony Blackburn-Starza 
Professor Sir John Gurdon of the University of Cambridge has been jointly awarded the Nobel Prize for his work on stem cells. He shares the prize for medicine or physiology with Professor Shinya Yamanaka from Japan...
05 March 2012 - by Cathy Holding 
A major clinical trial to investigate a stem cell treatment for chronic ischemic heart disease (IHD) – a leading cause of death around the world – has begun in the US...
21 November 2011 - by Rosemary Paxman 
A US drug company is abandoning its research into a novel paralysis treatment using embryonic stem cells, due to current economic conditions....
28 September 2009 - by Dr Marianne Kennedy 
The US Food and Drug Administration (FDA) has granted approval to NeuralStem Inc., a Maryland-based biotherapeutics company, to conduct the first human trial using neural stem cells for treatment of amyotrophic lateral sclerosis (ALS). ALS is a type of motor neuron disease often referred to as 'Lou Gehrig's' and 'Maladie de Charcot'. The late-onset condition, of unknown cause, affects approximately two in 100,000 people, including the UK physicist Stephen Hawking and US rock gui...
08 March 2004 - by BioNews 
The use of blood stem cells to treat heart attack patients shows promise, but can lead to complications, South Korean researchers say. A new study published in the Lancet shows that although the experimental treatment can help repair damaged heart tissue, it also causes side effects in many patients. As...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation